A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy

A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy

In their new article in the Journal of Investigative Dermatology, Tseng et al. (2021) confirm that the sensitivity of melanoma cells to anti‒PD-L1 checkpoint inhibitor therapy is correlated with high PD-L1 surface expression. By blocking PD-L1 membrane clearing, controlled by LRP1 and PAI-1, the exp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of investigative dermatology 2021-11, Vol.141 (11), p.2566-2568
Hauptverfasser: Del Rosso, Mario, Fibbi, Gabriella, Laurenzana, Anna, Margheri, Francesca, Chillà, Anastasia
Format: Artikel
Sprache:eng
Schlagworte:
Humans
Immunologic Factors
Immunotherapy
Melanoma - drug therapy
Plasminogen Activator Inhibitor 1
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In their new article in the Journal of Investigative Dermatology, Tseng et al. (2021) confirm that the sensitivity of melanoma cells to anti‒PD-L1 checkpoint inhibitor therapy is correlated with high PD-L1 surface expression. By blocking PD-L1 membrane clearing, controlled by LRP1 and PAI-1, the expression of high-cell-surface levels of PD-L1 was maintained.
ISSN:0022-202X
1523-1747
DOI:10.1016/j.jid.2021.05.004